Studies Find Plant-Based Spray Can Provide Pain Relief from Inflammatory Skin Conditions What are the main findings?

Response: This paper presents tolerance and efficacy results of a dermo-cosmetic spray containing protein-free extract of Rhealba oat plantlets and extract of Uncaria tomentosa from five clinical studies in adults and children with eczema (atopic dermatitis and hand eczema), adults with psoriasis and adults who had undergone a dermatological procedure.

The results of these five studies indicate that the dermo-cosmetic spray is well tolerated and provides effective relief of symptoms associated with cutaneous pain in subjects with inflammatory skin diseases or following post acts.
Investigator-assessed physical and functional signs of inflammation were reduced throughout all studies, with the size of reduction meeting statistical significance.

Subject assessed sensations of discomfort perceived as painful were also reduced throughout each of the studies and the dermo-cosmetic spray provided an appreciable soothing effect.

Subjects with atopic dermatitis, psoriasis and hands eczema reported notable improvements in quality of life between the beginning and end of the relevant study. What should readers take away from your report?

Response: The results of these studies indicate that the dermo-cosmetic spray containing protein-free extract of Rhealba oat plantlets and extract of Uncaria tomentosa can be a useful addition to therapy for inflammatory skin diseases such as atopic dermatitis, hands eczema and psoriasis with an immediate reduction in cutaneous pain, a rapid soothing effect and overall increase of QoL.

And that people who have undergone dermatological procedures may also benefit from its soothing properties during the post-procedural healing period.

The two plant extracts included in the spray may aid in reducing cutaneous pain by anti-inflammatory activity and direct action on nociceptors. What recommendations do you have for future research as a result of this work?

Response: The consistency of findings across the studies strengthens the outcomes from the individual studies and indicates a potential benefit of the spray across a number of dermatological conditions. 

As the results on cutaneous pain linked to nociception, are good, we now investigate two new clinical studies.

The first one, in herpes zoster because is a pain reference for dermatologists and there are a lot of clinical cases with pain symptomatology refer to indication.

Indeed, in the absence of risk factors for complicated courses, Herpes Zoster, usually, is a self-limiting disease. Goals of treatment are to improve the outcomes concerning quality of life of the affected patients, extent and duration of cutaneous symptoms and intensity and duration of acute zoster-associated pain. Since postherpetic neuralgia is the most frequent sequela of Herpes Zoster, reducing its incidence is a major secondary treatment goal.

The second one is a large Phase 4 post-marketing study, with of course as indications, chronic inflammatory skin diseases, but expanding the indications to Rosacea (vascular form), Patient under radiotherapy or chemotherapy, paresthesia, trichodynia and molluscum contagiosum.


Reich, A., Lopez Estebaranz, J., Bahadoran, P., Guillot, P., Carballido, F. and Saint Aroman, M. (2020), A spray containing extracts of oat plantlets and Uncaria tomentosa relieves pain associated with chronic inflammatory skin diseases and dermatological procedures. J Eur Acad Dermatol Venereol, 34: 3-11. doi:10.1111/jdv.16428

[wysija_form id=”3″]


The information on is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.